Mississauga, Canada

Kirk McCallum

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2000-2013

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kirk McCallum: Innovator in Biopharmaceuticals

Introduction

Kirk McCallum is a notable inventor based in Mississauga, Canada. He has made significant contributions to the field of biopharmaceuticals, particularly in the area of glucagon-like peptide-2 receptors. With a total of 3 patents, his work has advanced the understanding and application of these important biological molecules.

Latest Patents

Kirk's latest patents include innovations related to cloned glucagon-like peptide-2 receptors. The first patent focuses on nucleotides and amino acid sequences encoding glucagon-like peptide-2 receptors, as well as recombinant host cells transformed with such nucleotides. This invention also outlines methods for using these receptors in drug screening and related applications. The second patent reiterates similar concepts, emphasizing the importance of these receptors in therapeutic contexts.

Career Highlights

Throughout his career, Kirk has worked with prominent companies in the biopharmaceutical sector. Notable among these are NPS Pharmaceuticals, Inc. and Allelix Biopharmaceuticals Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.

Collaborations

Kirk has collaborated with esteemed colleagues, including Donald G Munroe and Ashwani K Gupta. These partnerships have fostered innovation and have been instrumental in advancing their shared research goals.

Conclusion

Kirk McCallum's contributions to the field of biopharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to impact drug development and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…